Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells

被引:24
作者
Jakubowicz-Gil, Joanna [1 ]
Langner, Ewa [3 ]
Rzeski, Wojciech [2 ,3 ]
机构
[1] Marie Curie Sklodowska Univ, Dept Comparat Anat & Anthropol, PL-20033 Lublin, Poland
[2] Marie Curie Sklodowska Univ, Dept Virol & Immunol, PL-20033 Lublin, Poland
[3] Inst Agr Med, Dept Med Biol, PL-20950 Lublin, Poland
关键词
Temodal; quercetin; astrocytoma; cell death; caspases; Hsps; LC3; MALIGNANT GLIOMA-CELLS; HEAT-SHOCK PROTEINS; FLAVONOID QUERCETIN; KINASE-B; APOPTOSIS; TEMOZOLOMIDE; TUMOR; GLIOBLASTOMA; INHIBITION; METABOLISM;
D O I
10.1016/S1734-1140(11)70506-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line. Our results indicate that quercetin was toxic and induced necrosis, whereas Temodal induced autophagy-mediated cell death most effectively. The amount of cell death directly correlated with drug concentration and length of exposure. During combined administration of both chugs, Temodal attenuated the cytotoxic effects of quercetin. Combinations of both drugs were effective in inducing programmed cell death, but the type of cell death was concentration-dependent. Co-administration of Temodal (100 mu M) with a low quercetin concentration (5 mu M) resulted in a very significant induction of autophagy; however, after treatment with quercetin at a higher concentration (30 mu M), apoptosis became the primary mechanism of cell death. The sequence of drug administration was also important. The highest number of dead cells was observed after simultaneous administration of both drugs or after pre-incubation with Temodal followed by treatment with quercetin. Apoptosis was identified through activation of the mitochondrial pathway including cleavage of caspase-3 and release of cytochrome c. Autophagy was identified through increased levels of LC3II. Our results indicate that Temodal and quercetin are synergistic inducers of programmed cell death, better together than applied separately. This drug combination appears to be a potent and promising therapeutic relevant to the treatment of gliomas.
引用
收藏
页码:403 / 416
页数:14
相关论文
共 44 条
[1]   Combination of lipids and emulsifiers enhances the absorption of orally administered quercetin in rats [J].
Azuma, K ;
Ippoushi, K ;
Ito, H ;
Higashio, H ;
Terao, J .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (06) :1706-1712
[2]   Fate of the flavonoid quercetin in human cell lines: Chemical instability and metabolism [J].
Boulton, DW ;
Walle, UK ;
Walle, T .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (03) :353-359
[3]   Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse [J].
Brada, M ;
Hoang-Xuan, K ;
Rampling, R ;
Dietrich, PY ;
Dirix, LY ;
Macdonald, D ;
Heimans, JJ ;
Zonnenberg, BA ;
Bravo-Marques, JM ;
Henriksson, R ;
Stupp, R ;
Yue, N ;
Bruner, J ;
Dugan, M ;
Rao, S ;
Zaknoen, S .
ANNALS OF ONCOLOGY, 2001, 12 (02) :259-266
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   Antiproliferative effect of quercetin in the human U138MG glioma cell line [J].
Braganhol, Elizandra ;
Zamin, Lauren L. ;
Delgado Canedo, Andres ;
Horn, Fabiana ;
Tamajusuku, Alessandra S. K. ;
Wink, Marcia R. ;
Salbego, Christianne ;
Battastini, Ana M. O. .
ANTI-CANCER DRUGS, 2006, 17 (06) :663-671
[6]  
Chowdhury SA, 2005, ANTICANCER RES, V25, P2055
[7]   Therapeutic applications of heat shock proteins and molecular chaperones [J].
Clark, JI .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (07) :1153-1160
[8]   Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects [J].
Conquer, JA ;
Maiani, G ;
Azzini, E ;
Raguzzini, A ;
Holub, BJ .
JOURNAL OF NUTRITION, 1998, 128 (03) :593-597
[9]  
Friedman HS, 2000, CLIN CANCER RES, V6, P2585
[10]   Targeting apoptosis pathways in cancer therapy [J].
Ghobrial, IM ;
Witzig, TE ;
Adjei, AA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (03) :178-194